1.	Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) Phase: Phase IV Type: Treatment Status: Active Age: 16 to 65 Sponsor: Other Protocol IDs: MCC-14178, NCT00361140
2.	Phase II/III Study of Standard and Novel Conditioning Therapy Followed By Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia or Hematologic Malignancy Phase: Phase III, Phase II Type: Treatment Status: Active Age: 4 to 70 Sponsor: Other Protocol IDs: RPCI-RP-9815, NCI-V99-1527, NCT00003816, RP 98-15
3.	Stem Cell Transplantation for Hematological Malignancies Phase: Phase III, Phase II Type: Treatment Status: Active Age: 35 and under Sponsor: Other Protocol IDs: 0005M52481, MT2000-12, 2000LS040, NCT00176839
4.	Randomized Study of Decitabine in Maintenance Therapy of AML Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2006-0358, NCT00398983
5.	Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy Phase: Phase III, Phase II Type: Treatment Status: Active Age: 12 to 55 Sponsor: Pharmaceutical / Industry Protocol IDs: GC P#02.01.001, NCT00469729
6.	Phase II/III Study of Disease-Specific High-Dose Conditioning Regimens Followed by Autologous Stem Cell Transplantation (Single or Tandem) in Patients With Hematologic Malignancies or Solid Tumors Phase: Phase III, Phase II Type: Treatment Status: Active Age: 4 and over Sponsor: NCI Protocol IDs: RPCI-I-72806, I 72806, NCT00536601
7.	Study of Autologous Peripheral Blood Stem Cell Transplantation in Patients With Acute Myeloid Leukemia Phase: Phase III, Phase II Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: UMN-MT2006-13, MT2006-13, NCT00630565
8.	Phase III Randomized Study of Nonmyeloablative Conditioning Comprising Low-Dose Total Body Irradiation With Versus Without Fludarabine Followed By HLA-Matched Related Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies at Low or Moderate Risk For Graft Rejection Phase: Phase III Type: Treatment Status: Active Age: Under 75 Sponsor: NCI Protocol IDs: FHCRC-1813.00, 5666, NCT00075478
9.	Phase III Randomized Study of Tipifarnib as Maintenance Therapy in Patients With Acute Myeloid Leukemia in Second or Subsequent Complete Remission or in First Complete Remission Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-E2902, E2902, NCT00093470
10.	Stem Cell Transplant for Hematological Malignancy Phase: Phase III Type: Treatment Status: Active Age: 54 and under Sponsor: Other Protocol IDs: 0107M05202, MT2001-02, NCT00176930
11.	Phase III Randomized Study of Myeloablative Versus Nonmyeloablative Transplant Conditioning in Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia Phase: Phase III Type: Treatment Status: Active Age: 65 and under Sponsor: NCI, NHLBI Protocol IDs: FHCRC-1992.00, 6170, NCT00322101, NHLBI-K23-HL084054-01A1
12.	A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I) Phase: Phase III Type: Treatment Status: Active Age: 60 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CLO34100405, NCT00317642
13.	Phase III Randomized Study of Conventional Combination Chemotherapy With Versus Without Gemtuzumab Ozogamicin in Young Patients With Newly Diagnosed Acute Myeloid Leukemia Phase: Phase III Type: Treatment Status: Active Age: Under 30 Sponsor: NCI Protocol IDs: COG-AAML0531, AAML0531, NCT00372593
14.	Phase III Randomized Study of Filgrastim (G-CSF)-Mobilized Matched-Sibling Donor Peripheral Blood Stem Cell Transplantation Versus G-CSF-Stimulated Matched-Sibling Donor Bone Marrow Transplantation in Patients With Hematologic Malignancies or Other Diseases Phase: Phase III Type: Treatment Status: Active Age: 16 to 65 Sponsor: NCI Protocol IDs: CBMTG-0601, NCT00438958
15.	IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 65 and under Sponsor: Other Protocol IDs: 2005-0366, NCT00469144
16.	Phase III Randomized Study of Induction and Consolidation Combination Chemotherapy With or Without Gemtuzumab Ozogamicin Followed By Maintenance Therapy Comprising Tretinoin, Mercaptopurine, and Methotrexate Versus Observation in Patients With Previously Untreated Low- or Intermediate-Risk Acute Promyelocytic Leukemia Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: SWOG-S0521, S0521, NCT00492856
17.	Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML Phase: Phase III Type: Treatment Status: Active Age: 50 to 75 Sponsor: NCI, Other Protocol IDs: SU-11122007-874, 97843, BMT190, NCT00568633, NCT00568633
18.	Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 2 to 55 Sponsor: NCI, NHLBI Protocol IDs: 385, BMT CTN 0402, U01 HL069294-05, NCT00406393
19.	Phase III Randomized Study of Induction Therapy Comprising Daunorubicin Hydrochloride and Cytarabine With or Without Midostaurin Followed by Consolidation Therapy Comprising High-Dose Cytarabine and Midostaurin Followed by Continuation Therapy Comprising Midostaurin Alone in Patients With Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia Phase: Phase III Type: Treatment Status: Active Age: 18 to 59 Sponsor: NCI Protocol IDs: CALGB-10603, CALGB 10603, EUDRACT-2006-006852-37, NCT00651261
20.	Randomized Allogeneic Azacitidine Study Phase: Phase III Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: 2008-0503, NCT00887068
21.	Phase I/II Pilot Study of Adoptive Immunotherapy With CD8+ WT1-Specific CTL Clones for Patients With Advanced Myelodysplastic Syndromes (MDS), Chronic Myelogenous Leukemia (CML), Acute Myeloid Leukemia (AML), or Acute Lymphoblastic Leukemia (ALL) After Allogeneic Hematopoietic Stem Cell Transplant Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 75 and under Sponsor: NCI Protocol IDs: FHCRC-1655.00, 5430, NCT00052520
22.	Phase I/II Study of Donor Lymphocyte Infusion in Patients With Persistent, Relapsed, or Progressing Malignancy After Nonmyeloablative Allogeneic Transplantation Phase: Phase II, Phase I Type: Treatment Status: Active Age: Any age Sponsor: NCI Protocol IDs: FHCRC-1803.00, 5606, NCT00068718
23.	Stem Cell Transplant for Hematologic Diseases and Renal Cell Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: H8713, NCT00058825
24.	Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers Phase: Phase II, Phase I Type: Treatment Status: Active Age: 12 to 60 Sponsor: Pharmaceutical / Industry Protocol IDs: CB001, NCT00089596
25.	Phase I/II Study of Pentostatin and Donor Lymphocyte Infusion in Preventing Graft Rejection in Cancer Patients With Low or Falling Donor T-Cell Chimerism After Nonmyeloablative Allogeneic Stem Cell Transplantation Phase: Phase II, Phase I Type: Treatment Status: Active Age: Under 75 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: FHCRC-1825.00, 5605, SUPERGEN-FHCRC-1825.00, NCT00096161